Novartis falls short in legal effort to undo FDA approval of MSN's Entresto generic

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto.

In a court decision filed this week in Washington, D.C., U.S. District Judge Dabney Friedrich rejected Novartis’ position that the FDA’s July approval of MSN’s Entresto generic was unlawful. In issuing the decision, the judge upheld MSN’s generic green light.